Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that has been shown to increase growth hormone and IGF-1 levels. It is an injectable peptide that generates greater natural production of HGH (Human Growth Hormone). It binds and stimulates human GHRH receptors with similar potency as our own natural GHRH. It has not been shown to significantly affect other pituitary hormones in the body.

 Tesamorelin is currently the most effective GH releasing hormone on the market. 

Gland Stimulated: Pituitary Gland 

  • Increases natural productions of HGH (human growth hormone)
  • Increases IGF-1 (Insulin Growth Factor – 1) without altering glucose parameters
  • Reduced triglycerides
  • Reduced Visceral Adipose Tissue (VAT)
  • Reduced Carotid Intima Media Size (cIMT)
  • Improved cognition in adults over the age of 60 

Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorelin is discontinued (depending upon the individual).

Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in Non-HIV-infected individuals.

According to one clinical study, 10.9 percent of patients who were given Tesamorelin experienced reductions in deep belly fat. These patients suffered from HIV. Reductions in trunk fat, waist size, and waist-to-hip ratios were recorded during the study. However, limbs and abdominal SC fat levels remained the same. During treatment, insulin-like growth factor 1 was boosted. However, glucose parameters were not altered. This drug didn’t trigger negative side effects in most patients. However, results were temporary, as patients who were switched to a placebo lost their improvements. The study lasted six months in total. Overall, visceral fat levels decreased by eighteen percent.